Moreover, as dopamine seems to be a regulator of NLRP3 activation in macrophages [50], studying the effect of different DOPA concentrations on the lymphocytes of PD patients will be of interest to verify the possible interaction among this drug, NLRP3 and miR-223-3p. This evidence concerns the gene NLRP3 and Parkinson disease.